TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Operating Expenses

Last Annual Value

254.22M

3-Year CAGR

38%

5-Year CAGR

43%

10-Year CAGR

27%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Operating Expenses

TMDX · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
254.22M
11.6%33.2%26.8% 
285.42M
18.2%23.1%N/A
479.95M
9.3%13.0%17.7%
1.34B
7.6%11.0%9.5%
1.01B
46.2%N/AN/A
388.60M
16.8%17.5%N/A
728.00M
-12.2%10.1%3.4%
248.13M
8.0%48.0%N/A
2.08B
12.6%-3.6%N/A
682.45M
0.8%3.0%8.6%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
532.90M
36.8%37.6%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69